# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed	l by the Registrant ⊠ l by a Party other than the Registrant □ ck the appropriate box:
	Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Definitive Proxy Statement  Definitive Additional Materials  Soliciting Material Pursuant to §240.14a-12
	BioSig Technologies, Inc. (Name of Registrant as Specified In Its Charter)  (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payr	nent of Filing Fee (Check all boxes that apply):
$\boxtimes$	No fee required.
	Fee paid previously with preliminary materials.
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



BIOSIG TECHNOLOGIES, INC.

2024 Annual Meeting Vote by December 30, 2024 11:59 PM ET



V59462-P21447

BIOSIG TECHNOLOGIES INC 12424 WILSHIRE BLVD., SUITE 745 LOS ANGELES CA 90025

# You invested in BIOSIG TECHNOLOGIES, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on December 31, 2024.

# Get informed before you vote

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to December 17, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

## Vote Virtually at the Meeting\*

December 31, 2024 10:00 a.m., ET

Virtually at:

www.virtualshareholdermeeting.com/BSGM2024

### **Smartphone users**

Point your camera here and vote without entering a control number



<sup>\*</sup>Please check the meeting materials for any special requirements for meeting attendance.

# THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

<ul> <li>01) Anthony Amato</li> <li>02) Frederick D. Hrkac</li> <li>03) Christopher A. Baer</li> <li>2. A proposal to approve an amendment to our Amended and Restated Certificate of Incorporation to effect, at the discretion of the Board but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company's stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of our common stock, par value \$0.001 per share ("Common Stock"), at a ratio in the range of 1-for-2 to 1-for-10, with the exact exchange ratio and timing to be determined by the Board in its discretion and included in a public announcement.</li> <li>3. A proposal to approve the Second Amendment to the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan to increase the total number of shares of Common Stock authorized for issuance under such plan by 3,500,000, to a total of 4,376,595 shares.</li> </ul>	<ul><li>✓ For</li></ul>
<ul> <li>01) Anthony Amato</li></ul>	
<ul> <li>01) Anthony Amato</li></ul>	
discretion of the Board but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company's stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of our common stock, par value \$0.001 per share ("Common Stock"), at a ratio in the range of 1-for-2 to 1-for-10, with the exact exchange ratio and timing to be determined by the Board in its discretion and included in a public announcement.  3. A proposal to approve the Second Amendment to the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan to increase the total number of shares of Common Stock authorized for issuance under such plan by 3,500,000, to a total of 4,376,595 shares.  4. A proposal to ratify the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.  NOTE: Such other business as may arise and that may properly be conducted at the Annual Meeting or any adjournment	For
increase the total number of shares of Common Stock authorized for issuance under such plan by 3,500,000, to a total of 4,376,595 shares.  4. A proposal to ratify the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.  NOTE: Such other business as may arise and that may properly be conducted at the Annual Meeting or any adjournment	
fiscal year ending December 31, 2024.  NOTE: Such other business as may arise and that may properly be conducted at the Annual Meeting or any adjournment	<b>⊘</b> For
	<b>⊘</b> For
от розгропетиент инстеот.	

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".